Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus.

Tsuneyasu Yoshida Hideaki TsujiAkira OnishiYudai Takase Mirei ShirakashiHideo OnizawaRyosuke HiwaKoji KitagoriShuji AkizukiRan NakashimaMasao TanakaHajime YoshifujiAkio Morinobu

Published in: Lupus science & medicine (2022)

SARS-CoV-2 vaccination did not significantly influence the medium-term subjective and objective disease activities or flares of SLE until 90 days after the second vaccination.

Keyphrases

disease activity
sars cov
systemic lupus erythematosus
rheumatoid arthritis
rheumatoid arthritis patients
preterm infants
ankylosing spondylitis
respiratory syndrome coronavirus
gestational age
juvenile idiopathic arthritis
sleep quality
binding protein